Publications by authors named "Jeffrey Tyner"

Claim this Profile
R
Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism.
Bryan Harris, Dinesh K Singh, Billy Truong, Michele Rhodes, Rachael Price, Jeffrey W Tyner

Cell Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of germline CHEK2 pathogenic variants on the risk of Acute Myeloid Leukemia and Myelodysplastic syndrome.
Fei Yang, Nicola Long, Jonathan C Savage, Jose Solis-Ruiz, Yu Li, Jeffrey W Tyner

Cancer Epidemiol Biomarkers Prev· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.
Jennifer N Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Jeffrey W Tyner

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia.
Melissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, Ariel Nguyen, Isabel Kenna, Jeffrey W Tyner

Cell Rep Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
m6a and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.
Jackson Brim-Edwards, Karen Morris, Quinlan Morrow, Stephen E Kurtz, Daniel Bottomly, Jeffrey W Tyner

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Daniel Chan, Yun Zheng, Jeffrey W Tyner, Wee Joo Chng, Wen Wen Chien

J Cancer Res Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies.
Stephen E Kurtz, Christopher A Eide, Andy Kaempf, Nicola Long, Alexandria Miller, Jeffrey W Tyner

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Therapeutic Implications of Mutations in Acute Myeloid Leukemia.
Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrozek, Jeffrey W Tyner

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.
Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier-Tardy, Fangyan Dai, Jeffrey W Tyner

Blood Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired resistance in cancer: towards targeted therapeutic strategies.
Alice Soragni, Erik S Knudsen, Thomas N O'Connor, Cristina E Tognon, Jeffrey W Tyner

Nat Rev Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia.
Sunil K Joshi, Ariane Huang, Janét Pittsenbarger, Ujwal Shinde, Camilo Posso, Jeffrey W Tyner

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Zhe Wang, Anna Skwarska, Gowri Poigaialwar, Sovira Chaudhry, Alba Rodriguez-Meira, Jeffrey W Tyner

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Drug Combination Strategies for Fusion Positive Leukemia.
Ariane Huang, Sofia R Beer, Christopher A Eide, Brian J Druker, Jeffrey W Tyner

Precis Oncogenom· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.
Basil Allen, Daniel Bottomly, Thomas Köhnke, Anthony Wang, Hsin-Yun Lin, Jeffrey W Tyner

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Jeffrey W Tyner

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly, Jeffrey W Tyner

Nat Genet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating targeted therapies in older patients with -mutated AML.
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner

Leuk Lymphoma· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge graphs facilitate prediction of drug response for acute myeloid leukemia.
Guangrong Qin, Yue Zhang, Jeffrey W Tyner, Christopher J Kemp, Ilya Shmulevich

iScience· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.
Bill H Chang, Karina Thiel-Klare, Jeffrey W Tyner

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.
Rucha V Modak, Katia G de Oliveira Rebola, John McClatchy, Mona Mohammadhosseini, Alisa Damnernsawad, Jeffrey W Tyner

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity.
Alan S Futran, Tao Lu, Katherine Amberg-Johnson, Jiayi Xu, Xiaoxiao Yang, Jeffrey W Tyner

iScience· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
James C Pino, Camilo Posso, Sunil K Joshi, Michael Nestor, Jamie Moon, Jeffrey W Tyner

Cell Rep Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML.
Vakul Mohanty, Natalia Baran, Yuefan Huang, Cassandra L Ramage, Laurie M Cooper, Jeffrey W Tyner

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Jeffrey W Tyner

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy, Cheryl A C Peretz, Alexander E Perl, Jeffrey W Tyner

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis